Podcast: USP's Tina Morris on New Biologics Chapters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Podcast: USP's Tina Morris on New Biologics Chapters


USP's Tina Morris on Biologics Standards

Vice-president for biologics and biotechnology, US Pharmacopeia's Tina Morris discusses plans for new monoclonal antibody chapters, a product-class approach, the need for industry input, efforts toward pharmacopeial harmonization, and more. Recorded LIVE at the USP 2011 Science and Standards Symposium, October 2011.
Interviewed by Angie Drakulich, senior managing editor.

Related podcast with USP's Matthew van Hook

Related podcast with Gillian Woollet

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here